<DOC>
	<DOCNO>NCT00992446</DOCNO>
	<brief_summary>This phase II trial study side effect well bortezomib vorinostat work treat patient non-Hodgkin lymphoma ( NHL ) patient ' stem cell ( autologous ) transplant . Bortezomib vorinostat laboratory may stop growth lymphoma cell make likely die block enzyme need cell growth . Giving bortezomib together vorinostat autologous stem cell transplant may thus kill lymphoma cell remain transplant .</brief_summary>
	<brief_title>Bortezomib Vorinostat Maintenance Therapy After Autologous Stem Cell Transplant Treating Patients With Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess toxicity combine vorinostat bortezomib maintenance therapy autologous stem cell transplant ( ASCT ) NHL . SECONDARY OBJECTIVES : I . Ability complete plan therapy . II . Time disease progression , event-free survival . III . Overall survival . OUTLINE : All patient receive carmustine intravenously ( IV ) 3 hour day -7 ; cytarabine IV twice daily ( BID ) 3 hour etoposide IV BID 2 hour day -6 -3 ; melphalan IV 30 minute day -2 . Only patient history cluster differentiation ( CD ) 20+ NHL receive additional rituximab IV day -19 -12 . Patients undergo ASCT day 0 . Patients receive bortezomib IV day 2 8 , vorinostat orally ( PO ) daily ( QD ) day 1-14 . Treatment bortezomib vorinostat repeat total 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow least 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT Diagnosis nonHodgkin 's lymphoma , transform Bcell lymphoma , follicular lymphoma , mantle cell lymphoma , diffuse large Bcell Tcell lymphoma , deem candidate autologous transplant American Heart Association class I : patient cardiac disease without result limitation physical activity ; ordinary physical activity cause undue fatigue , palpitation , dyspnea , anginal pain ; additionally , patient &gt; 60 year age must leave ventricular ejection fraction least &gt; = 40 % demonstrate multi gated acquisition scan ( MUGA ) echocardiogram ( Echo ) Total bilirubin = &lt; 1.5 mg/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 3 x upper limit normal Creatinine clearance ( CrCL ) ( calculate creatinine clearance permit ) &gt; 40 mL/min Diffusing capacity lung carbon monoxide ( DLCO ) , forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) &gt; = 50 % predict ( correct hemoglobin ) Autologous graft minimum &gt; = 3.0 x 10^6 CD34+ cells/kg ; CD34 select Signed inform consent Female patient childbearing potential negative serum pregnancy test betahuman chorionic gonadotropin ( hCG ) Female patient either postmenopausal , free menses &gt; = 2 year , surgically sterilize , willing use 2 adequate barrier method contraception prevent pregnancy agree abstain heterosexual activity throughout study Male patient agree use adequate method contraception duration study INCLUSION CRITERIA FOR MAINTENANCE THERAPY 30120 day post ASCT nonHodgkin 's lymphoma CrCL &gt; = 40 ml/min Platelets ( PLT ) &gt; = 75,000 cells/mm^3 5 day recovery ASCT nadir Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm^3 5 day recovery ASCT nadir Total bilirubin ( TB ) = &lt; 1.5 x upper limit normal ( ULN ) AST/ALT = &lt; 2.5 x ULN EXCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT Karnofsky performance score &lt; 70 % Uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical improvement ) Pregnant breastfeed Fertile men woman unwilling use contraceptive technique time transplant one month post maintenance therapy Prior autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) Patients evidence myelodysplastic syndrome ( MDS ) /acute myeloid leukemia ( AML ) abnormal cytogenetics analysis indicative MDS pretransplant bone marrow examination Prolonged correct QT interval ( QTC ) electrocardiogram ( EKG ) Poorlycontrolled diabetes mellitus ( DM ) &gt; = grade 2 peripheral neuropathy Prior history human immunodeficiency virus ( HIV ) positivity know history hepatitis B C Previous history hypersensitivity bortezomib , boron , mannitol ; know hypersensitivity component study drug analog Require therapeutic anticoagulation treatment , especially Coumadin Patient chemotherapy , radiotherapy , biological therapy , within 30 day ( 42 day nitrosoureas mitomycin C ) recover adverse event due agent administer 30 day earlier Patient currently participate participate study investigational compound devise within 30 day initial dose study drug ( ) Patient prior treatment histone deacetylase ( HDAC ) inhibitor ( e.g. , romidepsin [ Depsipeptide ] , NSC630176 , MS 275 , LAQ824 , belinostat [ PXD101 ] , LBH589 , MGCD0103 , CRA024781 , etc ) ; patient receive compound HDAC inhibitorlike activity , valproic acid , antitumor therapy enroll study ; patient receive compounds indication , e.g . valproic acid epilepsy , may enroll 30day washout period History central nervous system ( CNS ) disease Symptomatic ascites pleural effusion Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug , substance abuse recent history ( within last year ) drug alcohol abuse Patient history prior malignancy exception complete resection basal cell carcinoma squamous cell carcinoma situ malignancy ; adequately treat localized prostate carcinoma prostatespecific antigen ( PSA ) &lt; 1.0 ; undergone potentially curative therapy evidence disease five year , and/or deem low risk recurrence his/her treat physician Patient history current evidence condition , therapy , laboratory ( lab ) abnormality might confound result study , interfere patient 's participation full duration study best interest patient participate Patient history gastrointestinal surgery procedure might , opinion investigator , interfere absorption swallow study drug EXCLUSION CRITERIA FOR MAINTENANCE THERAPY &gt; = grade 2 peripheral neuropathy within 14 day begin maintenance therapy Prolonged QTC Poorlycontrolled DM Myocardial infarction ( MI ) ASCT develop dilate cardiomyopathy ASCT Untreated systemic infection Potassium ( K ) magnesium ( Mg ) &gt; = grade 2 toxicity Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiogram ( ECG ) abnormality screen must document investigator medically relevant Patient hypersensitivity VELCADE ( bortezomib ) , boron , mannitol Female subject pregnant lactating ; confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilize woman Female patient lactate positive serum pregnancy test screening period , positive urine pregnancy test day 1 first dose study drug , applicable Serious medical psychiatric illness likely interfere participation clinical study Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Participation clinical trial investigational agent include trial , within 14 day start trial throughout duration trial Radiation therapy within 3 week randomization ; enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>NHL</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>